Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

[1]  E. Winer,et al.  Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort. , 2012 .

[2]  M. Federico,et al.  Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment , 2012 .

[3]  C. Nabhan,et al.  Trends in Incidence and Outcome in T-Cell Lymphoma Since 1992: A SEER Database Analysis , 2012 .

[4]  B. Coiffier,et al.  A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study , 2012 .

[5]  R. Advani,et al.  A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. , 2012 .

[6]  R. Advani,et al.  Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. , 2012 .

[7]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Matthew Greenwood,et al.  Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Burris,et al.  Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin , 2011 .

[10]  K. Savage.  Update: Peripheral T-Cell Lymphomas , 2011, Current hematologic malignancy reports.

[11]  J. Vose,et al.  Peripheral T-cell lymphoma. , 2011, Blood.

[12]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Reimer.  Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas , 2010, Advances in hematology.

[14]  J. Vose,et al.  Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma , 2010, CA: a cancer journal for clinicians.

[15]  R. Advani,et al.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[17]  G. Pérez-Manga,et al.  Hematopoietic SCT for peripheral T-cell lymphoma , 2008, Bone Marrow Transplantation.

[18]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Horwitz.  Management of peripheral T-cell non-Hodgkin's lymphoma , 2007, Current opinion in oncology.

[20]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[21]  S. Steinberg,et al.  Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma , 2006, Clinical Cancer Research.

[22]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  S. Pileri,et al.  Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  R. Ueda,et al.  Phenotypic analysis of peripheral T cell lymphoma among the Japanese , 1993, Acta pathologica japonica.

[26]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .